Drug compliance in patients with systemic scleroderma
- 274 Downloads
Although drug compliance is a crucial component of treatment effectiveness in chronic diseases, it has never been evaluated in patients with systemic scleroderma. Therefore, the aim of this descriptive study was to determine the drug compliance rate in systemic scleroderma patients and to identify risk factors for noncompliance in these patients. A cross-sectional observational study was conducted. All patients with systemic scleroderma (n = 41) who visited a rheumatic center and signed an informed consent form were included. Data were obtained during structured interviews with patients and from medical records. The Compliance Questionnaire Rheumatology (CQR) was used to determine patient compliance. The relationships between compliance rate and demographic and clinical characteristics were examined. The mean CQR score was 75 %. Based on a dichotomous rating, only 42 % of the patients achieved a satisfactory compliance rate (≥80 %). No relationships between various demographic and clinical characteristics and CQR score expressed as continuous or dichotomous variables were found. This study represents the first evaluation of drug compliance in patients with systemic scleroderma. Many noncompliant patients were identified, but no common risk factors for noncompliance were discovered. The reasons for noncompliance seem to depend on the personal features of the patients.
KeywordsAdherence Patient compliance Questionnaire Rheumatology Systemic scleroderma
This work was supported by a grant from Charles University in Prague (SVV 265 005).
- 4.Sabaté E (ed) (2003) Adherence to long-term therapies: Evidence for action. World Health Organization, GenevaGoogle Scholar
- 13.Ware J, Kosinski M, Dewey J (2000) How to score version two of the SF-36 Health Survey. QualityMetric, LincolnGoogle Scholar
- 17.Streiner DL, Norman GR (1989) Health measurement scales. Oxford University Press, Oxford, p 175Google Scholar
- 21.Meier FMP, Frommer KW, Dinser R et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-200742
- 26.Sultan N, Pope JE, Clements PJ, Scleroderma Trials Study Group (2004) The Health Assessment Questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology 43(4):472–478PubMedCrossRefGoogle Scholar